GLP 1R, GIPR, and GCGR: Targets for Obesity and Diabetes Sino Biological Glucagon like peptide 1 (GLP 1) receptor agonists are incretin analogues that promote glucose mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP 1 receptor agonists and GLP 1 and glucose dependent insulinotropic Upcoming wave of hormone based therapies set to change field of diabetes, obesity care Effects of GLP 1 (blue arrows), glucagon (red arrows) and GIP (green Download Scientific Diagram The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit